(Q40980387)

25 September 2017

1 reference

title

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? (English)

1 reference

25 September 2017

1 reference

1 reference

1 reference

1 reference

Blanchet PJ

1

1 reference

25 September 2017

Gomez-Mancilla B

series ordinal

2

1 reference

25 September 2017

Di Paolo T

series ordinal

3

1 reference

25 September 2017

Bédard PJ

series ordinal

4

1 reference

25 September 2017

publication date

1 January 1995

1 reference

Fundamental and Clinical Pharmacology

25 September 2017

published in

1 reference

25 September 2017

volume

9

1 reference

25 September 2017

issue

5

1 reference

25 September 2017

page(s)

434-442

1 reference

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1995.TB00518.X

Partial dopamine agonist therapy of levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1995.TB00518.X

Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1995.TB00518.X

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1995.TB00518.X

Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.1995.TB00518.X

10.1111/J.1472-8206.1995.TB00518.X

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference